Anika Capital Expenditures vs Begin Period Cash Flow Analysis
ANIK Stock | USD 17.87 0.04 0.22% |
Anika Therapeutics financial indicator trend analysis is way more than just evaluating Anika Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Anika Therapeutics is a good investment. Please check the relationship between Anika Therapeutics Capital Expenditures and its Begin Period Cash Flow accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anika Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.
Capital Expenditures vs Begin Period Cash Flow
Capital Expenditures vs Begin Period Cash Flow Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Anika Therapeutics Capital Expenditures account and Begin Period Cash Flow. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Anika Therapeutics' Capital Expenditures and Begin Period Cash Flow is 0.48. Overlapping area represents the amount of variation of Capital Expenditures that can explain the historical movement of Begin Period Cash Flow in the same time period over historical financial statements of Anika Therapeutics, assuming nothing else is changed. The correlation between historical values of Anika Therapeutics' Capital Expenditures and Begin Period Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Expenditures of Anika Therapeutics are associated (or correlated) with its Begin Period Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Begin Period Cash Flow has no effect on the direction of Capital Expenditures i.e., Anika Therapeutics' Capital Expenditures and Begin Period Cash Flow go up and down completely randomly.
Correlation Coefficient | 0.48 |
Relationship Direction | Positive |
Relationship Strength | Weak |
Capital Expenditures
Capital Expenditures are funds used by Anika Therapeutics to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Anika Therapeutics operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Most indicators from Anika Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Anika Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anika Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.At this time, Anika Therapeutics' Selling General Administrative is quite stable compared to the past year. Enterprise Value is expected to rise to about 537.5 M this year, although the value of Tax Provision is projected to rise to (3.7 M).
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 82.9M | 93.6M | 103.1M | 108.2M | Total Revenue | 147.8M | 156.2M | 166.7M | 175.0M |
Anika Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Anika Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Anika Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 330.7M | 365.6M | 347.5M | 349.1M | 270.6M | 148.0M | |
Other Current Liab | 11.3M | 26.3M | 20.4M | 16.0M | 17.8M | 18.7M | |
Total Current Liabilities | 16.3M | 36.9M | 29.8M | 27.9M | 31.1M | 32.6M | |
Total Stockholder Equity | 288.4M | 272.4M | 287.1M | 285.6M | 212.3M | 120.9M | |
Property Plant And Equipment Net | 73.6M | 73.2M | 68.6M | 79.0M | 75.0M | 78.7M | |
Net Debt | (136.1M) | (74.9M) | (75.1M) | (55.4M) | (43.8M) | (46.0M) | |
Retained Earnings | 245.4M | 221.4M | 225.6M | 210.7M | 128.1M | 71.7M | |
Accounts Payable | 3.8M | 9.0M | 7.6M | 9.1M | 9.9M | 10.4M | |
Cash | 157.5M | 95.8M | 94.4M | 86.3M | 72.9M | 54.9M | |
Non Current Assets Total | 96.4M | 188.2M | 179.0M | 179.6M | 107.3M | 55.4M | |
Cash And Short Term Investments | 184.9M | 98.3M | 94.4M | 86.3M | 72.9M | 62.2M | |
Net Receivables | 23.1M | 24.1M | 29.8M | 34.6M | 36.0M | 37.8M | |
Common Stock Shares Outstanding | 14.4M | 14.2M | 14.6M | 14.6M | 14.7M | 12.7M | |
Liabilities And Stockholders Equity | 330.7M | 365.6M | 347.5M | 349.1M | 270.6M | 148.0M | |
Non Current Liabilities Total | 26.1M | 56.3M | 30.7M | 35.7M | 27.3M | 15.3M | |
Inventory | 22.0M | 46.2M | 36.0M | 39.8M | 46.4M | 48.7M | |
Other Current Assets | 1.4M | 8.8M | 16.6M | 17.7M | 8.1M | 8.5M | |
Other Stockholder Equity | 48.7M | 55.4M | 67.1M | 81.1M | 90.0M | 54.8M | |
Total Liab | 42.3M | 93.2M | 60.5M | 63.6M | 58.4M | 61.3M | |
Property Plant And Equipment Gross | 73.6M | 73.2M | 47.6M | 48.3M | 122.6M | 128.8M | |
Total Current Assets | 235.7M | 177.4M | 168.5M | 169.5M | 163.3M | 92.6M | |
Accumulated Other Comprehensive Income | (5.9M) | (4.5M) | (5.7M) | (6.4M) | (5.9M) | (6.2M) | |
Non Currrent Assets Other | 7.5M | 15.4M | 20.3M | 17.2M | 18.7M | 19.6M | |
Common Stock Total Equity | 147K | 142K | 143K | 144K | 167.9K | 139.2K | |
Short Term Investments | 70.0M | 27.5M | 2.5M | 34.6M | 39.8M | 41.8M | |
Other Assets | (1.4M) | 38.0M | 20.3M | 18.7M | 21.5M | 22.5M | |
Property Plant Equipment | 50.8M | 50.6M | 47.6M | 48.3M | 55.5M | 32.3M | |
Other Liab | 4.7M | 35.5M | 11.4M | 6.8M | 6.2M | 8.1M | |
Good Will | 7.7M | 8.4M | 7.8M | 7.3M | 7.6M | 8.0M | |
Intangible Assets | 7.6M | 91.2M | 82.4M | 74.6M | 4.6M | 4.4M | |
Net Tangible Assets | 294.5M | 193.7M | 216.2M | 232.4M | 267.3M | 227.7M | |
Retained Earnings Total Equity | 245.4M | 221.4M | 225.6M | 210.7M | 242.3M | 149.3M | |
Capital Surpluse | 48.7M | 55.4M | 67.1M | 81.1M | 73.0M | 52.5M | |
Deferred Long Term Liab | 4.3M | 11.9M | 10.2M | 6.4M | 7.4M | 7.2M | |
Non Current Liabilities Other | 357K | 23.6M | 1.3M | 398K | 404K | 383.8K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anika Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anika Therapeutics. If investors know Anika will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anika Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.51) | Earnings Share (6.64) | Revenue Per Share 11.139 | Quarterly Revenue Growth (0.07) | Return On Assets (0.04) |
The market value of Anika Therapeutics is measured differently than its book value, which is the value of Anika that is recorded on the company's balance sheet. Investors also form their own opinion of Anika Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Anika Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anika Therapeutics' market value can be influenced by many factors that don't directly affect Anika Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Anika Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Anika Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anika Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.